Somatostatin receptor pathophysiology in the neuroendocrine system

References

• Ben-Jonathan N, Hnasko R. Dopamine as a prolactin (PRL) inhibitor. Endocr. Rev. 22(6), 724–763 (2001).
   PubMed Web of Science ®Google Scholar
• Guillemin R. Hypothalamic hormones a.k.a. hypothalamic releasing factors. J. Endocrinol. 184(1), 11–28 (2005).
   PubMed Web of Science ®Google Scholar
• Ferone D, Gatto F, Arvigo M et al. The clinical-molecular interface of somatostatin, dopamine and their receptors in pituitary pathophysiology. J. Mol. Endocrinol. 42(5), 361–370 (2009).
   PubMed Web of Science ®Google Scholar
• Miller GM, Alexander JM, Bikkal HA, Katznelson L, Zervas NT, Klibanski A. Somatostatin receptor subtype gene expression in pituitary adenomas. J. Clin. Endocrinol. Metab. 80(4), 1386–1392 (1995).
   PubMed Web of Science ®Google Scholar
• Hofland LJ, Lamberts SW. Somatostatin receptor subtype expression in human tumors. Ann. Oncol. 12(Suppl. 2), S31–S36 (2001).
   PubMed Web of Science ®Google Scholar
• Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ. Octreotide. N. Engl. J. Med. 334(4), 246–254 (1996).
   PubMed Web of Science ®Google Scholar
• Patel YC. Somatostatin and its receptor family. Front. Neuroendocrinol. 20(3), 157–198 (1999).
   PubMed Web of Science ®Google Scholar
• Møller LN, Stidsen CE, Hartmann B, Holst JJ. Somatostatin receptors. Biochim. Biophys. Acta 1616(1), 1–84 (2003).
   PubMed Web of Science ®Google Scholar
• Srirajaskanthan R, Watkins J, Marelli L, Khan K, Caplin ME. Expression of somatostatin and dopamine 2 receptors in neuroendocrine tumours and the potential role for new biotherapies. Neuroendocrinology 89(3), 308–314 (2009).
   PubMed Web of Science ®Google Scholar
• Papotti M, Bongiovanni M, Volante M et al. Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. Virchows Arch. 440(5), 461–475 (2002).
   PubMed Web of Science ®Google Scholar
• Hofland LJ, Lamberts SW. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr. Rev. 24(1), 28–47 (2003).
   PubMed Web of Science ®Google Scholar
• Reubi JC, Maurer R, von Werder K, Torhorst J, Klijn JG, Lamberts SW. Somatostatin receptors in human endocrine tumors. Cancer Res. 47(2), 551–558 (1987).
   PubMed Web of Science ®Google Scholar
• Pivonello R, Ferone D, Lombardi G, Colao A, Lamberts SW, Hofland LJ. Novel insights in dopamine receptor physiology. Eur. J. Endocrinol. 156(Suppl. 1), S13–S21 (2007).
   Google Scholar
• Stefaneanu L, Kovacs K, Horvath E, Buchfelder M, Fahlbusch R, Lancranjan L. Dopamine D2 receptor gene expression in human adenohypophysial adenomas. Endocrine 14(3), 329–336 (2001).
   PubMed Web of Science ®Google Scholar
• Saveanu A, Jaquet P, Brue T, Barlier A. Relevance of coexpression of somatostatin and dopamine D2 receptors in pituitary adenomas. Mol. Cell. Endocrinol. 286(1–2), 206–213 (2008).
   PubMed Web of Science ®Google Scholar
• Pivonello R, Ferone D, de Herder WW et al. Dopamine receptor expression and function in corticotroph ectopic tumors. J. Clin. Endocrinol. Metab. 92(1), 65–69 (2007).
   PubMed Web of Science ®Google Scholar
• de Bruin C, Feelders RA, Lamberts SW, Hofland LJ. Somatostatin and dopamine receptors as targets for medical treatment of Cushing’s syndrome. Rev. Endocr. Metab. Disord. 10(2), 91–102 (2009).
   PubMed Web of Science ®Google Scholar
• Grant M, Patel RC, Kumar U. The role of subtype-specific ligand binding and the C-tail domain in dimer formation of human somatostatin receptors. J. Biol. Chem. 279(37), 38636–38643 (2004).
   PubMed Web of Science ®Google Scholar
• Patel YC. Molecular pharmacology of somatostatin receptor subtypes. J. Endocrinol. Invest. 20(6), 348–367 (1997).
   PubMed Web of Science ®Google Scholar
• Law SF, Woulfe D, Reisine T. Somatostatin receptor activation of cellular effector systems. Cell. Signal. 7(1), 1–8 (1995).
   PubMed Web of Science ®Google Scholar
• Schally AV. Oncological applications of somatostatin analogues. Cancer Res. 48(24 Pt 1), 6977–6985 (1988).
   PubMed Web of Science ®Google Scholar
• Lamberts SW, Krenning EP, Reubi JC. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr. Rev. 12(4), 450–482 (1991).
   PubMed Web of Science ®Google Scholar
• Hofland LJ, Visser-Wisselaar HA, Lamberts SW. Somatostatin analogs: clinical application in relation to human somatostatin receptor subtypes. Biochem. Pharmacol. 50(3), 287–297 (1995).
   PubMed Web of Science ®Google Scholar
• Florio T. Somatostatin/somatostatin receptor signalling: phosphotyrosine phosphatases. Mol. Cell. Endocrinol. 286(1–2), 40–48 (2008).
   PubMed Web of Science ®Google Scholar
• Schonbrunn A. Selective agonism in somatostatin receptor signaling and regulation. Mol. Cell. Endocrinol. 286(1–2), 35–39 (2008).
   PubMed Web of Science ®Google Scholar
• Ferone D, Pivonello R, Van Hagen PM et al. Quantitative and functional expression of somatostatin receptor subtypes in human thymocytes. Am. J. Physiol. Endocrinol. Metab. 283(5), E1056–E1066 (2002).
   Google Scholar
• Ferrante E, Pellegrini C, Bondioni S et al. Octreotide promotes apoptosis in human somatotroph tumor cells by activating somatostatin receptor type 2. Endocr. Relat. Cancer 13(3), 955–962 (2006).
   PubMed Web of Science ®Google Scholar
• Tulipano G, Schulz S. Novel insights in somatostatin receptor physiology. Eur. J. Endocrinol. 156(Suppl. 1), S3–11 (2007).
   PubMedGoogle Scholar
• Pivonello R, Ferone D, Lamberts SW, Colao A. Cabergoline plus lanreotide for ectopic Cushing’s syndrome. N. Engl. J. Med. 352(23), 2457–2458 (2005).
   PubMed Web of Science ®Google Scholar
• Weckbecker G, Lewis I, Albert R, Schmid HA, Hoyer D, Bruns C. Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nat. Rev. Drug Discov. 2(12), 999–1017 (2003).
   PubMed Web of Science ®Google Scholar
• Theodoropoulou M, Zhang J, Laupheimer S et al. Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression. Cancer Res. 66(3), 1576–1582 (2006).
   PubMed Web of Science ®Google Scholar
• Ben-Shlomo A, Melmed S. Pituitary somatostatin receptor signaling. Trends Endocrinol. Metab. 21(3), 123–133 (2010).
   PubMed Web of Science ®Google Scholar
• Chang JP, Habibi HR, Yu Y, Moussavi M, Grey CL, Pemberton JG. Calcium and other signalling pathways in neuroendocrine regulation of somatotroph functions. Cell Calcium 51(3–4), 240–252 (2012).
   PubMed Web of Science ®Google Scholar
• Ludvigsen E, Stridsberg M, Taylor JE, Culler MD, Oberg K, Janson ET. Subtype selective interactions of somatostatin and somatostatin analogs with sst1, sst2, and sst5 in BON-1 cells. Med. Oncol. 21(3), 285–295 (2004).
   PubMed Web of Science ®Google Scholar
• Reubi JC, Laissue J, Krenning E, Lamberts SW. Somatostatin receptors in human cancer: incidence, characteristics, functional correlates and clinical implications. J. Steroid Biochem. Mol. Biol. 43(1–3), 27–35 (1992).
   PubMed Web of Science ®Google Scholar
• Reubi JC, Schaer JC, Laissue JA, Waser B. Somatostatin receptors and their subtypes in human tumors and in peritumoral vessels. Metab. Clin. Exp. 45(8 Suppl. 1), 39–41 (1996).
   PubMed Web of Science ®Google Scholar
• Papotti M, Croce S, Bellò M et al. Expression of somatostatin receptor types 2, 3 and 5 in biopsies and surgical specimens of human lung tumours. Correlation with preoperative octreotide scintigraphy. Virchows Arch. 439(6), 787–797 (2001).
   PubMed Web of Science ®Google Scholar
• Gatto F, Hofland LJ. The role of somatostatin and dopamine D2 receptors in endocrine tumors. Endocr. Relat. Cancer 18(6), R233–R251 (2011).
   Google Scholar
• Ruscica M, Arvigo M, Steffani L, Ferone D, Magni P. somatostatin, somatostatin analogs and somatostatin receptor dynamics in the biology of cancer progression. Curr. Mol. Med. (2012) (Epub ahead of print).
   Google Scholar
• Ruscica M, Arvigo M, Gatto F et al. Regulation of prostate cancer cell proliferation by somatostatin receptor activation. Mol. Cell. Endocrinol. 315(1–2), 254–262 (2010).
   PubMed Web of Science ®Google Scholar
• Nouel D, Gaudriault G, Houle M et al. Differential internalization of somatostatin in COS-7 cells transfected with SST1 and SST2 receptor subtypes: a confocal microscopic study using novel fluorescent somatostatin derivatives. Endocrinology 138(1), 296–306 (1997).
   PubMed Web of Science ®Google Scholar
• Sarret P, Nouel D, Dal Farra C, Vincent JP, Beaudet A, Mazella J. Receptor-mediated internalization is critical for the inhibition of the expression of growth hormone by somatostatin in the pituitary cell line AtT-20. J. Biol. Chem. 274(27), 19294–19300 (1999).
   PubMed Web of Science ®Google Scholar
• Halmos G, Schally AV, Sun B, Davis R, Bostwick DG, Plonowski A. High expression of somatostatin receptors and messenger ribonucleic acid for its receptor subtypes in organ-confined and locally advanced human prostate cancers. J. Clin. Endocrinol. Metab. 85(7), 2564–2571 (2000).
   PubMed Web of Science ®Google Scholar
• Reubi JC, Waser B, Schaer JC, Markwalder R. Somatostatin receptors in human prostate and prostate cancer. J. Clin. Endocrinol. Metab. 80(9), 2806–2814 (1995).
   PubMed Web of Science ®Google Scholar
• Cervia D, Zizzari P, Pavan B et al. Biological activity of somatostatin receptors in GC rat tumour somatotrophs: evidence with sst1–sst5 receptor-selective nonpeptidyl agonists. Neuropharmacology 44(5), 672–685 (2003).
   PubMed Web of Science ®Google Scholar
• Cervia D, Petrucci C, Bluet-Pajot MT, Epelbaum J, Bagnoli P. Inhibitory control of growth hormone secretion by somatostatin in rat pituitary GC cells: sst(2) but not sst(1) receptors are coupled to inhibition of single-cell intracellular free calcium concentrations. Neuroendocrinology 76(2), 99–110 (2002).
   PubMed Web of Science ®Google Scholar
• Yasuda K, Rens-Domiano S, Breder CD et al. Cloning of a novel somatostatin receptor, SSTR3, coupled to adenylylcyclase. J. Biol. Chem. 267(28), 20422–20428 (1992).
   PubMed Web of Science ®Google Scholar
• Lahlou H, Guillermet J, Hortala M et al. Molecular signaling of somatostatin receptors. Ann. NY Acad. Sci. 1014, 121–131 (2004).
   PubMed Web of Science ®Google Scholar
• Ben-Shlomo A, Schmid H, Wawrowsky K et al. Differential ligand-mediated pituitary somatostatin receptor subtype signaling: implications for corticotroph tumor therapy. J. Clin. Endocrinol. Metab. 94(11), 4342–4350 (2009).
   PubMed Web of Science ®Google Scholar
• Gurevich VV, Gurevich EV. The structural basis of arrestin-mediated regulation of G-protein-coupled receptors. Pharmacol. Ther. 110(3), 465–502 (2006).
   PubMed Web of Science ®Google Scholar
• Oakley RH, Laporte SA, Holt JA, Caron MG, Barak LS. Differential affinities of visual arrestin, β arrestin 1, and β arrestin 2 for G protein-coupled receptors delineate two major classes of receptors. J. Biol. Chem. 275(22), 17201–17210 (2000).
   PubMed Web of Science ®Google Scholar
• Liu Q, Bee MS, Schonbrunn A. Site specificity of agonist and second messenger-activated kinases for somatostatin receptor subtype 2A (Sst2A) phosphorylation. Mol. Pharmacol. 76(1), 68–80 (2009).
   PubMed Web of Science ®Google Scholar
• Pöll F, Doll C, Schulz S. Rapid dephosphorylation of G protein-coupled receptors by protein phosphatase 1β is required for termination of ß-arrestin-dependent signaling. J. Biol. Chem. 286(38), 32931–32936 (2011).
   PubMed Web of Science ®Google Scholar
• Peverelli E, Mantovani G, Calebiro D et al. The third intracellular loop of the human somatostatin receptor 5 is crucial for arrestin binding and receptor internalization after somatostatin stimulation. Mol. Endocrinol. 22(3), 676–688 (2008).
   PubMed Web of Science ®Google Scholar
• Liu Q, Dewi DA, Liu W, Bee MS, Schonbrunn A. Distinct phosphorylation sites in the SST2A somatostatin receptor control internalization, desensitization, and arrestin binding. Mol. Pharmacol. 73(2), 292–304 (2008).
   PubMed Web of Science ®Google Scholar
• Jacobs S, Schulz S. Intracellular trafficking of somatostatin receptors. Mol. Cell Endocrinol. 286(1–2), 58–62 (2008).
   PubMed Web of Science ®Google Scholar
• Reubi JC, Waser B, Cescato R, Gloor B, Stettler C, Christ E. Internalized somatostatin receptor subtype 2 in neuroendocrine tumors of octreotide-treated patients. J. Clin. Endocrinol. Metab. 95(5), 2343–2350 (2010).
   PubMed Web of Science ®Google Scholar
• Kreuzer OJ, Krisch B, Déry O, Bunnett NW, Meyerhof W. Agonist-mediated endocytosis of rat somatostatin receptor subtype 3 involves β-arrestin and clathrin coated vesicles. J. Neuroendocrinol. 13(3), 279–287 (2001).
   PubMed Web of Science ®Google Scholar
• Gagnon AW, Kallal L, Benovic JL. Role of clathrin-mediated endocytosis in agonist-induced down-regulation of the β2-adrenergic receptor. J. Biol. Chem. 273(12), 6976–6981 (1998).
   PubMed Web of Science ®Google Scholar
• Gray JA, Roth BL. Cell biology. A last GASP for GPCRs? Science 297(5581), 529–531 (2002).
   PubMed Web of Science ®Google Scholar
• Pippig S, Andexinger S, Lohse MJ. Sequestration and recycling of β 2-adrenergic receptors permit receptor resensitization. Mol. Pharmacol. 47(4), 666–676 (1995).
   PubMed Web of Science ®Google Scholar
• Tsao PI, von Zastrow M. Type-specific sorting of G protein-coupled receptors after endocytosis. J. Biol. Chem. 275(15), 11130–11140 (2000).
   PubMed Web of Science ®Google Scholar
• Yu SS, Lefkowitz RJ, Hausdorff WP. β-adrenergic receptor sequestration. A potential mechanism of receptor resensitization. J. Biol. Chem. 268(1), 337–341 (1993).
   PubMed Web of Science ®Google Scholar
• Hofland LJ, van der Hoek J, Feelders R, van der Lely AJ, de Herder W, Lamberts SW. Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects. J. Endocrinol. Invest. 28(Suppl. 11), 36–42 (2005).
   PubMedGoogle Scholar
• Pöll F, Lehmann D, Illing S et al. Pasireotide and octreotide stimulate distinct patterns of sst2A somatostatin receptor phosphorylation. Mol. Endocrinol. 24(2), 436–446 (2010).
   PubMed Web of Science ®Google Scholar
• Kao YJ, Ghosh M, Schonbrunn A. Ligand-dependent mechanisms of sst2A receptor trafficking: role of site-specific phosphorylation and receptor activation in the actions of biased somatostatin agonists. Mol. Endocrinol. 25(6), 1040–1054 (2011).
   PubMed Web of Science ®Google Scholar
• Lesche S, Lehmann D, Nagel F, Schmid HA, Schulz S. Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro. J. Clin. Endocrinol. Metab. 94(2), 654–661 (2009).
   PubMed Web of Science ®Google Scholar
• Durán-Prado M, Malagón MM, Gracia-Navarro F, Castaño JP. Dimerization of G protein-coupled receptors: new avenues for somatostatin receptor signalling, control and functioning. Mol. Cell. Endocrinol. 286(1–2), 63–68 (2008).
   PubMed Web of Science ®Google Scholar
• Csaba Z, Peineau S, Dournaud P. Molecular mechanisms of somatostatin receptor trafficking. J. Mol. Endocrinol. 48(1), R1–R12 (2012).
   PubMed Web of Science ®Google Scholar
• Saveanu A, Gunz G, Dufour H et al. Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas. J. Clin. Endocrinol. Metab. 86(1), 140–145 (2001).
   PubMed Web of Science ®Google Scholar
• Baragli A, Alturaihi H, Watt HL, Abdallah A, Kumar U. Heterooligomerization of human dopamine receptor 2 and somatostatin receptor 2 co-immunoprecipitation and fluorescence resonance energy transfer analysis. Cell. Signal. 19(11), 2304–2316 (2007).
   PubMed Web of Science ®Google Scholar
• Patel RC, Kumar U, Lamb DC et al. Ligand binding to somatostatin receptors induces receptor-specific oligomer formation in live cells. Proc. Natl Acad. Sci. USA 99(5), 3294–3299 (2002).
   PubMed Web of Science ®Google Scholar
• Rocheville M, Lange DC, Kumar U, Sasi R, Patel RC, Patel YC. Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers. J. Biol. Chem. 275(11), 7862–7869 (2000).
   PubMed Web of Science ®Google Scholar
• Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC, Patel YC. Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 288(5463), 154–157 (2000).
   PubMed Web of Science ®Google Scholar
• Pfeiffer M, Koch T, Schröder H et al. Homo- and heterodimerization of somatostatin receptor subtypes. Inactivation of sst(3) receptor function by heterodimerization with sst(2A). J. Biol. Chem. 276(17), 14027–14036 (2001).
   PubMed Web of Science ®Google Scholar
• Grant M, Alturaihi H, Jaquet P, Collier B, Kumar U. Cell growth inhibition and functioning of human somatostatin receptor type 2 are modulated by receptor heterodimerization. Mol. Endocrinol. 22(10), 2278–2292 (2008).
   PubMed Web of Science ®Google Scholar
• Grant M, Collier B, Kumar U. Agonist-dependent dissociation of human somatostatin receptor 2 dimers: a role in receptor trafficking. J. Biol. Chem. 279(35), 36179–36183 (2004).
   PubMed Web of Science ®Google Scholar
• Cescato R, Schulz S, Waser B et al. Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists. J. Nucl. Med. 47(3), 502–511 (2006).
   PubMed Web of Science ®Google Scholar
• Tulipano G, Stumm R, Pfeiffer M, Kreienkamp HJ, Höllt V, Schulz S. Differential β-arrestin trafficking and endosomal sorting of somatostatin receptor subtypes. J. Biol. Chem. 279(20), 21374–21382 (2004).
   PubMed Web of Science ®Google Scholar
• Arvigo M, Gatto F, Ruscica M et al. Somatostatin and dopamine receptor interaction in prostate and lung cancer cell lines. J. Endocrinol. 207(3), 309–317 (2010).
   PubMed Web of Science ®Google Scholar
• Hofland LJ, Feelders RA, de Herder WW, Lamberts SW. Pituitary tumours: the sst/D2 receptors as molecular targets. Mol. Cell. Endocrinol. 326(1–2), 89–98 (2010).
   PubMed Web of Science ®Google Scholar
• Gatto F, Barbieri F, Gatti M et al. Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma response to somatostatin analogues and dopastatins. Clin. Endocrinol. (Oxf.) 76(3), 407–414 (2012).
   PubMed Web of Science ®Google Scholar
• Culler MD. Somatostatin-dopamine chimeras: a novel approach to treatment of neuroendocrine tumors. Horm. Metab. Res. 43(12), 854–857 (2011).
   PubMed Web of Science ®Google Scholar
• Somvanshi RK, Billova S, Kharmate G, Rajput PS, Kumar U. C-tail mediated modulation of somatostatin receptor type-4 homo- and heterodimerizations and signaling. Cell. Signal. 21(9), 1396–1414 (2009).
   PubMed Web of Science ®Google Scholar